Table 3. Most frequently amplified and deleted regions in glioblastoma samples.
| Event | N | Region | Genes |
|---|---|---|---|
| Amplification | 2 | 4q11-q12 | DCUN1D4, LRRC66, SGCB, SPATA18, SCFD2, FIP1L1, LNX1, CHIC2, GSX2, PDGFRA, KIT, KDR, SRD5A3, TMEM165, CLOCK, PDCL2 |
| Amplification | 14 | 7p12.2-p11.2 | VWC2, ZPBP, IKZF1, FIGNL1, DDC, GRB10, COBL, POM121L12, VSTM2A, SEC61G, EGFR, LANCL2, SEPT14, ZNF713, GBAS, PSPH, CCT6A, SUMF2, PHKG1, CHCHD2 |
| Amplification | 2 | 7q31.2 | CAV2, CAV1, MET, CAPZA2 |
| Amplification | 4 | 12q13.2-q13.3 | NEUROD4, OR9K2, OR10A7, OR6C74, OR6C6, OR6C1, OR6C3, OR6C75, OR6C65, PHC1B, OR6C76, OR6C2, OR6C70, OR6C68, OR6C4, OR2AP1, OR10P1, METTL7B, ITGA7, BLOC1S1, RDH5, CD63, GDF11, SARNP, ORMDL2, DNAJC14, MMP19, WIBG, DGKA, SILV, CDK2, RAB5B, SUOX, IKZF4, RPS26, ERBB3, PA2G4, ZC3H10, FAM62A, MYL6, SMARCC2, RNF41, OBFC2B, SLC39A5, ANKRD52, COQ10A, CS, CNPY2, PAN2, IL23A, STAT2, APOF, TIMELESS, MIP, SPRYD4, GLS2, RBMS2, BAZ2A, ATP5B, PTGES3, NACA, PRIM1 |
| Amplification | 3 | 12q14.3-q15 | CAND1, DYRK2 |
| Deletion | 2 | 1p32.3 | DMRTA2, FAF1 |
| Deletion | 20 | 9p22.1-p21.3 | SLC24A2, MLLT3, KIAA1797, PTPLAD2, IFNB1, IFNW1, IFNA21, IFNA4, IFNA7, IFNA10, IFNA16, IFNA17, IFNA14, IFNA5, KLHL9, IFNA6, IFNA13, IFNA2, IFNA8, IFNA1, MTAP, C9orf53, CDKN2A, CDKN2B, DMRTA1, ELAVL2, C9orf134 |
| Deletion | 2 | 10q23.2-q23.31 | PAPSS2, ATAD1, PTEN |
The genes of potential importance are shown in bold. N, number of GBM cases.